Efficacy and safety of oxygen-sparing nasal reservoir cannula for treatment of pediatric hypoxemic pneumonia in Uganda: a pilot randomized clinical trial

Jerry Mulondo¹, Stella Maleni¹, Hellen Aanyu-Tukamuhebwa², Ezekiel Mupere²,³, Alfred Onubia Andama⁴, Chin Hei Ng⁵, Stephen Burkot⁵, Ella M. E. Forgie⁶, Qaasim Mian⁶, Christine M. Bachman⁵, Gerard Rummery⁷, Daniel Lieberman⁵, David Bell⁵,⁸, Michael T. Hawkes⁶,⁹,¹⁰,¹¹,¹²*, and Akos Somoskovi⁵†

Abstract

Background: Oxygen is an essential therapy for hypoxemia but is scarce in low-income settings. Oxygen conserving devices optimize delivery, but to date have been designed for adults in high-income settings. Here we present the development and clinical pilot study of an oxygen-sparing nasal reservoir cannula (OSNRC) for pediatric use in low-income settings.

Methods: (1) Pre-clinical development of a novel OSNRC using a simulated respiratory circuit with metabolic simulator and anatomically accurate face-airway models. Simulated breathing waveforms were designed based on airway resistance, lung compliance, respiratory rate, and tidal volume of spontaneous breathing for three disease conditions. (2) Pilot, randomized, controlled, non-blinded, cross-over study of the OSNRC vs standard nasal cannula (SNC) among children hospitalized with hypoxemic pneumonia in Uganda. Eight children were randomized to OSNRC followed by SNC, and eight were randomized to SNC followed by OSNRC.

(Continued on next page)
Results: The laboratory simulation showed that the OSNRC provided the same or higher fraction of inspired oxygen at approximately 2.5-times lower flow rate compared to SNC. The flow savings ratio exhibited a linear relationship with the OSNRC volume to tidal volume ratio with a slope that varied with breathing waveforms. The range of performance from different breathing waveforms defined a performance envelope of the OSNRC. Two mask sizes (30 mL and 50 mL) provided sufficient coverage for patients between the 3rd and 97th percentile in our targeted age range. In the clinical pilot study, the rise in capillary blood pCO\(_2\) was similar in the OSNRC and SNC groups, suggesting that the OSNRC was not associated with CO\(_2\) retention. There were no significant differences between OSNRC and SNC with respect to clinical adverse events, lactate levels, pH, and SpO\(_2\). The OSNRC group had a higher mean SpO\(_2\) than the SNC group (adjusted mean difference, 1.4, 95% confidence interval 1.1 to 1.8), showing oxygen delivery enhancement.

Conclusion: The OSNRC enhances oxygen delivery without causing CO\(_2\) retention and appears to be well-tolerated by pediatric patients. If safety, efficacy and tolerability are confirmed in larger trials, this device has the potential to optimize oxygen delivery in children in low-resource settings, reducing the global burden of pediatric pneumonia.

Trial registration: The trial was retrospectively registered (International Standard Registered Clinical/Social Study Number (ISRCTN): 15216845; Date of registration: 15 July 2020).

Keywords: Oxygen, Pneumonia, Africa, Child, Nasal Canula

Background

Pneumonia is the leading cause of death among children under 5 years old globally [1, 2], accounting for 15% of all childhood deaths [3]. Hypoxemia is a potentially fatal complication of pneumonia, and the risk of death increases with increasing severity of hypoxemia [2, 4–6].

Oxygen is an essential supportive treatment of hypoxemia, and reduces the mortality associated with severe pneumonia [7, 8]. However, deficiencies in the delivery and sustainability of oxygen to hypoxic infants and children vary significantly in resource-limited settings [9]. Compressed oxygen cylinders are widely used but they may be expensive and difficult to transport, requiring regular replenishment and a functional supply chain [10]. Oxygen concentrators generate oxygen on site and may be less expensive; however, their use requires an uninterrupted power supply [8]. Central piped oxygen requires costly infrastructure that may be impractical for most hospitals in resource-limited countries. Medical grade oxygen is thus scarce in low-income settings.

Several methods are available for attaching oxygen to the patient [8]. Nasal prongs are optimal in terms of safety and efficacy, and are widely used in hospitals globally. Nasal or nasopharyngeal catheters are alternatives recommended by the World Health Organization (WHO) [8]. Facemasks, head boxes, incubators and tents may also be used, but are associated with oxygen waste and may not be appropriate where oxygen is in short supply.

Oxygen conserving devices (OCDs) function by changing the interface (e.g., reservoirs and transtracheal catheters) or changing the oxygen delivery system (e.g., demand oxygen delivery systems, DODS). These devices achieve a flow savings ratio (FSR), defined as the ratio of oxygen flow rate using a standard nasal cannula (SNC) to the oxygen flow rate with the device which produces the same clinical effect. Several previous studies have examined different oxygen-conserving techniques, primarily developed for adult patients with chronic hypoxemia due to chronic obstructive pulmonary disease (COPD), to reduce costs of long-term oxygen therapy. The principles underlying oxygen-sparing include: bypassing the dead space of the upper airway (e.g., surgically implanted transtracheal catheters) [11–13]; interrupting the flow during exhalation (e.g., DODS); and storing exhaled oxygen in a reservoir to make it available at the next inhalation (e.g., Pendant Conserving Nasal Cannula, PNC) [14, 15]. Examples of DODS include AccuO2 and CR-50, which can achieve FSRs of 9.9 ± 7.3 and 2.6 ± 1.0, respectively [16]. Reservoir masks, a common OCD, are used in combination with a SNC, and they are available for clinical use. Storing oxygen in the reservoir space during exhalation allows the patient to inspire a higher concentration of oxygen without increasing flow from the oxygen tank or concentrator at the next inhalation. This enables a reduction in the oxygen flow while maintaining the same peripheral oxygen saturation (SpO\(_2\)), reducing the overall volume needed and cost of oxygen therapy [17]. However, re-breathing exhaled carbon dioxide (CO\(_2\)) is a potential limitation of this strategy that could lead to hypercarbia and acidosis. Oxygen conserving reservoirs could be a simple, yet important tool for improving the efficiency of oxygen delivery in resource limited settings [18]. The PNC is typically used in adults but not pediatric patients because of the relatively large dead space for the smaller tidal volume in children.
However, this limitation may be overcome by placing the reservoir directly at the nose which reduces the volume of dead space in the excess tubing.

The objective of this study was to design and optimize an oxygen-sparing nasal reservoir cannula (OSNRC) and collect pilot data on its safety and efficacy among Ugandan children hospitalized with hypoxemic pneumonia. Our aim was to reserve highly saturated oxygen during exhalation to be re-inhaled, while minimizing re-intake of exhaled CO₂.

**Methods**

**Experimental apparatus**

We hypothesized that the RC would reduce the flow rate of oxygen required to deliver an equal or higher FiO₂ per oxygen delivered (L/min) compared with SNC alone. We speculated that the primary disadvantage of the RC was associated with increased CO₂ levels in exhaled air that could potentially lead to elevated toxicity levels. We tested this hypothesis using an experimental respiratory circuit.

An image and a schematic of the experimental apparatus are shown in Fig. 1. A series of anatomically accurate face-airway models were created by digitally combining three-dimensional (3D) images of faces [19] and CT scan of airways from the nostrils to the trachea [20]. 3D printed versions of the models, representing newborns to 5-year-olds, coupled with the ASL 5000 breathing simulator (IngMar Medical, Pittsburgh, PA) formed the complete breathing circuit (Fig. 1b).

Oxygen was supplied through a SNC or an OSNRC from standard medical grade oxygen cylinders. Oxygen flow rate was recorded using TSI 4040 flowmeter (TSI, Shoreview, MN). A built-in oxygen sensor recorded oxygen concentration inside the breathing simulator. Metabolic production of CO₂ was simulated in the system by injecting CO₂ through a port of the breathing simulator. End-tidal CO₂ (ETCO₂) was measured at the nostril using the Oxigraf O2Cap (Oxigraf, Inc., Sunnyvale, CA). The CO₂ production rate for each patient age was set by titrating the CO₂ flow rate until the ETCO₂ reached 5% under conditions of spontaneous breathing. The CO₂ flow rate was quantified using an Alicat M-10SLPM-D/5 M mass flowmeter (Alicat Scientific, Tucson, AZ). The empirically determined CO₂ production rate was applied to all experiments of the same patient age. All measurements were taken when the mean quantity within each breathing cycle reached steady state.

**Breathing waveforms**

The simulated breathing waveforms were designed based on published values for airway resistance [21], lung
compliance [21], respiratory rate [22], and tidal volume [23, 24] of spontaneous breathing (called normal). Breathing waveforms of three different disease conditions for each age were created using modified parameters (lung compliance, respiratory rate and inhalation-to-exhalation ratio). Examples of the breathing waveforms used in this study are shown in Fig. 1d.

**OSNRC volume sizing**

The design of the OSNRC required us to balance several factors and determine appropriate sizes for the intended users. Larger mask volumes tend to provide larger FSRs at the risk of increasing CO₂ retention and/or patient tolerability. We defined a minimum FSR of 1.8 and a maximum ETCO₂ 9% under no flow conditions.

The FSR was defined as:

\[
\frac{Q_{SNC}}{Q_{OSNRC}} = \frac{\text{Reference flow rate with SNC}}{\text{Equivalent flow rate with OSNRC}}
\]

where \(Q_{SNC}\) is the reference flow rate with SNC and \(Q_{OSNRC}\) is the flow rate with OSNRC to achieve the

---

**Fig. 2** Design of oxygen-sparing nasal reservoir cannula (OSNRC) based on oxygen sparing and CO₂ retention. a-c. The fraction of inspired oxygen (FiO₂) was higher at a given flow rate for the OSNRC (circle, solid line) compared to the SNC (square, dashed). The breathing simulator used a flow waveform resembling a patient with pneumonia. The tidal volume approximated that of an 8 kg (a), 12 kg (b) and 16 kg child (c), respectively. Two OSNRC sizes were used: 30 mL (a and b) and 50 mL (c). Data shown represent results from a single simulation at each condition. The flow savings ratio (FSR) was calculated to be 1.8 to 2.6. d. FSR as a function of OSNRC volume to tidal volume ratio. e. End-tidal CO₂ (ETCO₂), measured at the outlet of the simulated respiratory circuit, as a function of OSNRC volume to tidal volume ratio, using constant age-appropriate CO₂ production in the circuit. f. OSNRC sizes (30 mL and 50 mL) were designed for patients from 8 kg to 26 kg. Sizes were bounded by minimum FSR of 1.8 (horizontal dashed line), maximum ETCO₂ of 9% (vertical dashed lines), and maximum FSR observed (solid lines). Colored regions represent the range of operating states of the OSNRC.
same fraction of inspired oxygen (FiO$_2$) as using the SNC with the reference flow rate.

**Tolerability**

As an initial assessment of the tolerability of the OSNRC for pediatric patients, a fit test was conducted on children without acute respiratory disease during their follow-up visits at the Chest Clinic of the Department of Pediatrics of Mulago Hospital in Kampala. Patients were examined with the prototype for up to 5 min. Information regarding placement, size and comfort was collected using a standardized questionnaire, provided in the Supplementary materials.

**Pilot clinical study**

We conducted a pilot study of the OSNRC children hospitalized with hypoxemic pneumonia at a large resource-limited hospital in Uganda, Mulago National Referral Hospital. Details of the study are given in Supplementary materials. In brief, infants and children under the age of 5 years hospitalized with hypoxemia (SpO$_2$ ≥ 85 and < 94%) were provided oxygen using the OSNRC for a period of 1 hour. As a control condition, each patient also received oxygen via SNC for another period of 1 hour. The order of OSNRC and SNC for each child was randomly assigned. Group A received oxygen using the OSNRC for Period 1, followed by SNC for Period 2. Group B received oxygen using the SNC for Period 1, followed by the OSNRC for Period 2. The flow rate of oxygen began at 1.5 to 2 L/min and was systematically titrated downward, as allowed, to maintain SpO$_2$ > 94%. Vital signs were recorded every 15 min. At the end of each hour, capillary blood gas (pH, pCO$_2$, pO$_2$, base excess, HCO$_3$ and lactate) was measured. Any adverse events were also noted. The primary focus of the trial was clinical safety of the OSNRC.

As the primary safety outcome, we examined CO$_2$ retention, as measured by the change in pCO$_2$ after 1 h on OSNRC versus SNC alone (Period 1). Secondary safety outcomes included: clinical adverse events, capillary blood gas pCO$_2$ above normal range (> 45 mmHg), lactate above normal range (> 3 mmol/L), acidosis (pH < 7.35), and refractory hypoxemia (SpO$_2$ < 90%) despite supplemental O$_2$ therapy at any time on OSNRC. In addition, we compared the temporal trends in pCO$_2$, pH, and lactate to the control group receiving O$_2$ by SNC. Secondary efficacy outcomes included oxygen utilization and SpO$_2$ at several O$_2$ flow rates, compared between OSNRC and SNC. These outcomes were specified a priori in the trial protocol. Capillary blood gas was measured using an iSTAT-1 handheld analyzer with CG4+ cartridges (Abbott Point of Care Inc., Princeton, NJ).

**Results**

**Pre-clinical evidence of oxygen sparing**

Using our experimental respiratory circuit (Fig. 1), the OSNRC provided higher FiO$_2$ at different flow rates, simulated patient sizes, and mask sizes (Fig. 2a-c). The same FiO$_2$ could be obtained with a lower flow rate when using the OSNRC, with a FSR of 1.8 to 2.6 under these conditions (Fig. 2a-c). The FSR ($Q_{SNC}/Q_{OSNRC}$) was measured for a range of OSNRC volumes between 14 and 60 mL and for different breathing waveforms. The FSR varied between 1.5 and 4 and exhibited a linear relationship with the OSNRC volume to tidal volume ratio (Fig. 2d). The slope of this linear regression depended on the breathing waveforms (Fig. 2d).

The range of performance from different breathing waveforms defined a performance envelope of the OSNRC. The risk of elevated ETCO$_2$ was evaluated with no oxygen flow, representing the worst-case condition. Similar to the FSR, ETCO$_2$ also scaled linearly with the OSNRC volume to tidal volume ratio (Fig. 2e).

Both FSR and ETCO$_2$ data were then used to determine the OSNRC inner volume for target patient demographics. We found that two mask sizes 30 mL and 50 mL would be sufficient to cover patients weighing between 8 to 26 kg (Fig. 2f), which corresponds to patients between the ages of 18 and 66 months, using the 3rd and 97th percentile for weight [24]. The smaller mask size could be used on participants weighing 8–13 kg, while the larger mask size could be used on participants weighing 14–26 kg.

**Table 1** Tolerability and fit testing of OSNRC

| Cohort (n = 6) |
|----------------|
| **Demographics** |
| Male sex, n (%) | 5 (83) |
| Age (months), median (IQR) | 36 (34–41) |
| Weight, median (IQR) | 14 (12–16) |
| **Mask size** |
| 30 mL | 3 (50) |
| 50 mL | 3 (50) |
| **Tolerability, n (%)** |
| Mask fits appropriately | 5 (83) |
| Patient can tolerate mask | 5 (83) |
| Mask placement easy to perform | 6 (100) |
| Patient can tolerate face band | 5 (83) |
| Face band placement easy to perform | 6 (100) |
| Mask size appropriate | 6 (100) |

Pulse oximetry employed the Rad-5$^*$ oximeter (Masimo Corp., Irvine, CA).
Tolerability
A fit test was performed on 6 patients (3 per OSNRC size) without respiratory disease as an initial assessment of the tolerability of the device (Table 1). The median (IQR) age in months was 37 (33–43) and 5 participants (83%) were male. The reservoir was appropriate in size for all 6 patients and the head band offered additional support for the device. The OSNRC was well-tolerated by 5 (83%) of the fit test participants. The patient who did not tolerate the OSNRC also did not tolerate the SNC.

Clinical safety of nasal reservoir cannula
To demonstrate safety, we next piloted the OSNRC in a small group of children with hypoxemia in a resource-limited setting. Sixteen participants were recruited between November 20, 2018 and May 24, 2019. The pilot study flow diagram is shown in Fig. 3. Baseline characteristics are shown in Table 2.

With respect to our primary safety outcome, we did not observe evidence of CO₂ retention during the first hour of treatment with the OSNRC (Fig. 4). The mean (SD) rise in capillary blood pCO₂ with OSNRC was 7.2 (2.6) mmHg compared to 6.8 (1.6) with SNC alone (Fig. 4a and b, difference in means 0.43 mmHg, 95%CI −2.8 to +1.9). Secondary safety outcomes are shown in Table 3. Notably, no statistically significant differences in OSNRC versus SNC alone were detected for any of the safety endpoints. Two patients in Group B using the SNC were withdrawn according to protocol after Period 1 because their capillary blood gas lactate levels were higher than the pre-defined threshold for early discontinuation.

---

**Fig. 3** Trial profile. Pilot study of oxygen sparing nasal reservoir cannula (OSNRC) versus standard nasal cannula (SNC) among Ugandan children hospitalized with hypoxemia (n = 16). The flowchart shows the two trial Periods 1 and 2, and the treatment received by patients in each Group A (OSNRC first, then SNC) and Group B (SNC first, then OSNRC) during each period. Two patients in Group B discontinued the trial after Period 1 (SNC) due to hyperlactatemia.
Table 2 Baseline characteristics of participants

|                                | Entire Cohort (n = 16) | Group A<sup>a</sup> (n = 8) | Group B<sup>b</sup> (n = 8) |
|--------------------------------|------------------------|-----------------------------|-----------------------------|
| **Demographics**               |                        |                             |                             |
| Male sex (n, %)                | 8 (50)                 | 5 (63)                      | 3 (38)                      |
| Age (months), median (IQR)     | 23 (17–29)             | 20 (15–28)                  | 26 (20–32)                  |
| **Past medical history**       |                        |                             |                             |
| Pneumonia                      | 6 (38)                 | 2 (25)                      | 4 (50)                      |
| Asthma                         | 1 (6)                  | 1 (13)                      | 0                           |
| HIV                            | 0                      | 0                           | 0                           |
| Malaria                        | 3 (17)                 | 0                           | 3 (38)                      |
| **Clinical examination**       |                        |                             |                             |
| Baseline SpO₂                  | 90 (88–93)             | 89 (88–92)                  | 90 (87–93)                  |
| 85–89%                         | 8 (50)                 | 4 (50)                      | 4 (50)                      |
| 90–94%                         | 8 (50)                 | 4 (50)                      | 4 (50)                      |
| Weight (kg), median (IQR)      | 11.4 (9.0–13.0)        | 11.5 (9.0–13.1)             | 10.9 (9.5–12.6)             |
| Temperature (°C), median (IQR) | 37.4 (37–37.9)         | 37.4 (37.1–37.5)            | 37.9 (37–38.1)              |
| Blood pressure (mmHg)<sup>3</sup> |                       |                             |                             |
| Systolic, median (IQR)         | 95 (92–101)            | 96 (87–104)                 | 95 (92–100)                 |
| Diastolic, median (IQR)        | 67 (62.5–78.5)         | 65 (60–72)                  | 73 (65–80)                  |
| Heart Rate (bpm), median (IQR) | 157 (138–168)          | 152 (142–160)               | 159 (135–179)               |
| Respiratory rate (bpm), median (IQR) | 63 (57.5–76) | 66 (60–76)                  | 63 (54–76)                  |
| Tachypnea                      | 16 (100)               | 8 (100)                     | 8 (100)                     |
| Delayed Capillary refill time  | 0                      | 0                           | 0                           |
| Absent or unequal breath sounds| 0                      | 0                           | 0                           |
| Wheeze                         | 1 (8)                  | 0                           | 1 (6)                       |
| Crackles                       | 12 (75)                | 6 (75)                      | 6 (75)                      |
| Stridor                        | 0                      | 0                           | 0                           |
| Rapid or shallow breathing     | 16 (100)               | 8 (100)                     | 8 (100)                     |
| Increased work of breathing    | 16 (100)               | 8 (100)                     | 8 (100)                     |
| Chest wall asymmetry           | 0                      | 0                           | 0                           |
| Consciousness                  |                        |                             |                             |
| Alert                          | 16 (100)               | 8 (100)                     | 8 (100)                     |
| Response to Voice              | 0                      | 0                           | 0                           |
| Response to pain               | 0                      | 0                           | 0                           |
| Unresponsive                   | 0                      | 0                           | 0                           |
| SICK scores                    | 2.1 (0.9–2.2)          | 1.5 (0.9–2.1)               | 2.1 (1.4–2.3)               |
| **Investigations, median (IQR)** |                      |                             |                             |
| Venous blood gas               |                        |                             |                             |
| Lactate (mmol/L)               | 1.8 (1.54–1.9)         | 1.9 (1.8–2)                 | 1.7 (1.4–2.0)               |
| pH                             | 7.4 (7.4–7.5)          | 7.4 (7.4–7.5)               | 7.5 (7.4–7.5)               |
| pCO₂ (mmHg)                    | 27 (24–32)             | 27 (25–32)                  | 28 (24–31)                  |
| paO₂ (mmHg)                    | 44 (43–47)             | 43 (42–46)                  | 45 (43–49)                  |
| BE (mmol/L)                    | -5 (−8 to −4)          | −6 (−9 to −5)               | −5 (−6 to −2)               |
| HCO₃ (mmol/L)                  | 19 (17–20)             | 18 (16–20)                  | 20 (18–21)                  |
| Blood glucose (mmol/L)         | 6 (5.2–6.9)            | 5.6 (5.1–6.5)               | 6.5 (5.5–7.0)               |
At admission, patients had evidence of compensated respiratory alkalosis, with low pCO$_2$ (median 27 mmHg, IQR 24 to 30), and negative base excess ($-5$ mmol/L, IQR $-8$ to $-4$, Table 2). A rise in the pCO$_2$ toward normal levels was observed in patients on OSNRC, of median magnitude 7.5 mmHg (IQR 5.2 to 7.9) and 2.2 mmHg (IQR 1.1 to 3.7) during periods 1 and 2, respectively. This rise in pCO$_2$ was similar in magnitude to patients on SNC ($p > 0.1$ for both period 1 and 2, Table 4). Of note, the rise in pCO$_2$ was associated with a reduction in the respiratory rate reflecting the normalization of the minute ventilation, and a statistically (but not clinically) significant decrease in the pH, without significant change in the base excess (Table 4 and Fig. 4). Notably, the magnitude of the change in blood gas parameters was similar in patients with

### Table 2 Baseline characteristics of participants (Continued)

| Hematologic parameters          | Entire Cohort ($n = 16$) | Group A$^a$ ($n = 8$) | Group B$^b$ ($n = 8$) |
|--------------------------------|--------------------------|-----------------------|-----------------------|
| Hemoglobin (g/dL)              | 11.1 (10–11.8)           | 11 (10–12.2)          | 11.1 (10–11.5)        |
| Hematocrit (%)                 | 35 (31–36)               | 34 (31–36)            | 34 (31–36)            |
| White blood cell count (x10$^3$ μL) | 13 (8–18)              | 10 (8–21)             | 15 (7–18)             |
| Platelet count (x10$^3$ μL)    | 396 (271–552)            | 424 (320–552)         | 396 (260–540)         |

Data represent n (%) unless otherwise specified

IQR Interquartile Range

$^a$Group A received OSNRC during Period 1, followed by SNC during Period 2

$^b$Group B received SNC during Period 1, followed by OSNRC during Period 2

Fig. 4 Clinical pilot data comparing oxygen-sparing nasal reservoir cannula (OSNRC) and standard nasal cannula (SNC) in hypoxemic Ugandan children. a and b. Normalization of hypocapnia with resolving tachypnea was observed in patients using both OSNRC and SNC, with no evidence of greater CO$_2$ retention in the OSNRC group relative to the SNC group. c and d. Capillary blood gas pH changes were similar in OSNRC and SNC groups. e. Evidence of oxygen sparing by the OSNRC. Peripheral oxygen saturation (SpO$_2$) increased with increasing oxygen flow rate in patients using both OSNRC and standard nasal cannula (SNC), but was comparatively higher at several flow rates with the OSNRC. In a linear mixed-effects model, the increase in SpO$_2$ was 1.6% for each 1 L/min increase in flow rate and was 1.4% higher for OSNRC, relative to SNC ($p < 0.0001$)
Table 3 Secondary safety outcomes

| Perioda,b | OSNRC | SNC |
|-----------|-------|-----|
| Clinical adverse event | 1 | 0 | 0 |
| | 2 | 0 | 0 |
| Severe adverse event | 1 | 0 | 0 |
| | 2 | 0 | 0 |
| pCO₂ > 45 mmHg | 1 | 0 | 0 |
| | 2 | 0 | 0 |
| pH < 7.35 | 1 | 2 (25)% | 1 (12) |
| | 2 | 1 (17) | 2 (25) |
| Lactate > 3 mmol/L | 1 | 0 | 2 (25) |
| | 2 | 1 (17)% | 0 |
| SpO₂ < 90% despite O₂ | 1 | 0 | 0 |
| | 2 | 0 | 0 |

Data represent the number (percent) of patients who experienced an adverse event with OSNRC and SNC (control)

aDuring Period 1, patients were treated with OSNRC (Group A, n = 8) or SNC (Group B, n = 8) for 1 hour
bDuring Period 2, patients were treated with OSNRC (Group B, n = 6) or SNC (Group A, n = 8) for 1 hour

OSNRC and SNC (Table 4 and Figure S1, Supplemental materials). No patients with OSNRC or SNC developed hypercapnia or acidosis at any point in the study.

Table 4 Change in vital signs and capillary blood gas parameters with OSNRC or SNC over study periods 1 and 2 of crossover RCT

| Perioda,b | OSNRC | SNC | P-valuec |
|-----------|-------|-----|----------|
| SpO₂ (%) | 1 | −1 (−2 to −0.75) | −1.5 (−2.2 to −1) | 0.44 |
| | 2 | −1.5 (−2.8 to −1) | 0 (−1 to 1.2) | 0.1 |
| RR (min⁻¹) | 1 | −2 (−6 to −1) | 0 (−7 to 2) | 0.7 |
| | 2 | 2 (2 to 4) | −3 (−5 to 0.5) | 0.1 |
| HR (min⁻¹) | 1 | −14 (−16 to −11) | 1 (−0.25 to 3.5) | 0.0086 |
| | 2 | 3 (−5.2 to 6) | −4 (−9.8 to 2.8) | 0.48 |
| pCO₂ (mm Hg) | 1 | 7.5 (7.2 to 7.9) | 7.6 (5 to 9.2) | 0.79 |
| | 2 | 2.2 (1.1 to 3.7) | 0.5 (−1.7 to 1.3) | 0.11 |
| pH | 1 | −0.063 (−0.073 to −0.041) | −0.073 (−0.11 to −0.035) | 0.44 |
| | 2 | −0.01 (−0.018 to −0.0065) | 0.0025 (−0.0092 to 0.0083) | 0.34 |
| Lactate (mmol/L) | 1 | −0.48 (−0.72 to −0.32) | 0.33 (−0.4 to 0.98) | 0.028 |
| | 2 | −0.13 (−0.15 to 0.13) | 0.3 (0.1 to 0.43) | 0.18 |
| Base excess (mmol/L) | 1 | 0.5 (0 to 2.2) | 0 (0 to 0.25) | 0.34 |
| | 2 | 0.5 (0 to 1) | −1 (−1.2 to 0.25) | 0.099 |

Data represent the median (interquartile range)

aDuring Period 1, patients were treated with OSNRC (Group A, n = 8) or SNC (Group B, n = 8) for 1 hour
bDuring Period 2, patients were treated with OSNRC (Group B, n = 6) or SNC (Group A, n = 8) for 1 hour
cRepresents p-value for difference between OSNRC and SNC treatments

for every 1 L/min increase in flow rate, and was 1.4% (95%CI 1.1 to 1.8, p < 0.0001) higher in the OSNRC group compared to SNC group (Table 5). On visual inspection, the increase in SpO₂ was most prominent at lower flow-rates, with no apparent difference at flow rates > 1 L/min (Fig. 4). The OSNRC was associated with an increase in SpO₂ equivalent to an incremental flow rate increase of 0.9 L/min, and an FSR of 1.5.

Discussion

Here we describe the design and pilot testing of a low-cost OSNRC to augment the delivery of oxygen to pediatric patients with hypoxemia. Pre-clinical optimization of the OSNRC design used a novel, anatomically accurate, artificial respiratory circuit, and demonstrated a FSR of 1.8 to 2.6 under simulated, physiologically relevant conditions. A pilot clinical study demonstrated safety (no observed difference in CO₂ retention), with no statistically or clinically significant differences in secondary safety endpoints in patients breathing oxygen by OSNRC, compared to SNC alone. Furthermore, clinical efficacy was suggested by the increased SpO₂ at a given flow rate observed in patients on the OSNRC. The OSNRC achieved a potential increase in SpO₂ equivalent to an incremental flow rate increase of 0.9 L/min and an FSR of 1.6. Of note, the OSNRC is versatile and could be used with any oxygen supply modality (cylinders or concentrators) that can be used by the SNC.

Several previous studies have examined oxygen-conserving techniques. Generally, these devices were
CO2 retention was one possible concern with our apparatus. A disproportionate burden of global pneumonia mortality was attributed to children, our OSNRC extends the utility of oxygen sparing reservoir systems to the pediatric age group, who bear a greater burden of acute respiratory disease in children. Transtracheal catheters have a FSR between 2 and 3 in comparison to oxygen administered at the nares [25–27]; however, they have obvious disadvantages associated with an invasive neck surgery and would not be appropriate for pediatric pneumonia in low-resource settings [28]. Commercial DODS systems AccuO2 and CR-50 have FSRs of 9.9 and 2.6, respectively [16, 29], but are prohibitively costly and not yet optimized for pediatrics. Reservoir systems (e.g., Pendant Conserving Nasal Cannula, PNC) [30] had a FSR of 3 in a previous study of adult patients [31]. One study using a lung simulator demonstrated a FSR of 1.1–1.3 for toddler to adolescent simulated patients [32]. In another report on COPD patients, improvement in oxygen saturation with the PNC was 3.3, 4.3 and 3.1% at 0.5 L/min, 1 L/min and 2 L/min oxygen flow rates, respectively [30]. By comparison, our OSNRC improved SpO2 by 1.4%, with an FSR of 1.5. Major advantages of reservoir systems include the simplicity and low cost relative to other oxygen-sparing devices. Furthermore, whereas previous devices were designed for adult patients, our OSNRC extends the utility of oxygen sparing reservoir systems to the pediatric age group, who bear a disproportionate burden of global pneumonia mortality.

Patient safety was the primary focus of the pilot study. CO2 retention was one possible concern with our apparatus, since the OSNRC re-circulates exhaled air enriched in both O2 and CO2. Previous studies in COPD patients revealed a small risk of CO2 retention during controlled oxygen therapy. However, CO2 retention was not observed in our study. Capillary blood gas monitoring demonstrated a correction of hypocapnia as tachypnea resolved with oxygen therapy. Changes in pCO2 were no different with the OSNRC than with SNC. Although some cases of clinically insignificant acidosis and hyperlactatemia were observed, these occurred with similar frequency in the OSNRC and SNC groups.

Our study had some limitations. The effectiveness of the OSNRC might have been compromised by improper facial fitting and/or poor tolerability in young children. To accommodate for varying facial profiles, two different sizes of OSNRC were designed, which could be chosen based on patient weight. Despite this, there was one patient for whom the OSNRC was not tolerated during fit testing; however, this was not a major factor in the clinical pilot study. Another limitation of our study was the short duration (1 h) for each period, during which patients were either using OSNRC or SNC, whereas a longer time of observation would be informative. We measured capillary blood gas and transcutaneous pCO2; other measurements (arterial blood gases, end tidal CO2, FiO2) would provide additional information on oxygen treatment and safety with OSNRC. Measurement of alveolar ventilation would also be desirable to directly examine CO2 retention. Sample size was limited and the findings of this study should be validated in a larger patient cohort.

Conclusions
Childhood pneumonia, the leading cause of childhood death globally, as well as other respiratory and cardiac illnesses, may lead to life-threatening hypoxemia. The OSNRC is low-cost and used in a similar manner to commonly used oxygen delivery devices, two important factors for its successful implementation in low- to middle-income countries. Introducing the OSNRC into clinical settings should be accompanied by training for nursing staff on pulse oximetry and accurate titration of oxygen flow rate to maximize the flow savings benefits of the OSNRC. Future directions for the OSNRC include larger clinical studies, using the FSR relative to SNC as a clinical endpoint, as well as possible commercialization of the device. If taken to scale globally, the OSNRC could reduce costs of oxygen supply by reducing oxygen consumption. Efforts to reduce costs and improve efficiency of oxygen delivery could significantly decrease the global burden of acute respiratory disease in children.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s12890-020-01267-8.

Additional file 1: Appendix 1. Supplementary Methods. Appendix 2. Tolerability questionnaire. Appendix 3. Supplemental figure.

Abbreviations
OCDs: Oxygen conserving devices; OSNRCs: Oxygen-sparing nasal reservoir cannulas; DODS: Demand oxygen delivery systems; COPD: Chronic obstructive pulmonary disease; PNC: Pendant conserving nasal cannula; SNC: Standard nasal cannula; SpO2: Peripheral oxygen saturation; 3D: Three-dimensional; ETCO2: End-tidal CO2, FiO2: Fraction of inspired oxygen.
Acknowledgements
We thank Sam Wailala (lab runner), Geoffrey Anguandia (lab technologist), Juliet Biboza, Esther Bisaso and Robinah Asaba (study nurses), David Gasperino and Michael Barbour (research and development). We also thank all the patients and their families.

Authors’ contributions
MTH had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis, including and especially any adverse effects. DL, AS, DB conceived the study. CMB, HAT, EM, AOA, and MTH obtained ethics and regulatory approvals for the clinical pilot study. SM, JM, and HAT oversaw the clinical pilot study and were responsible for patient care. JM, EMEF, and MTH performed the data analysis. JM, EMEF, CHN, and MTH wrote the first draft of the manuscript. HAT, EM, AOA, DL, AS, DB, CHN, CMB, GR, and MTH interpreted the findings and critically reviewed the manuscript. QM wrote the first draft of the manuscript and critically reviewed the manuscript. All authors have read and approved the manuscript.

Funding
This study was funded by the Intellectual Ventures Global Good Fund. The funder provided support in the form of salaries for authors DL, CMB, SB, CHN, AS, and DB but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the authors’ contributions.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
The study was approved by the Mulago Hospital Research and Ethics Committee (Kampala, Uganda, Ref: MHRREC 1075), the Western Institutional Review Board (Seattle, WA, Study Number: 1188233), the University of Alberta Research Ethics Board Biomedical Panel (Edmonton, Canada; ref: Pro00089057) and the Uganda National Council for Science and Technology. Accompanying parents or legal guardians provided written informed consent at the time of enrolment.

Consent for publication
Not applicable.

Competing interests
DL, CMB, SB, are CHN current employees of Intellectual Ventures Laboratory, which co-developed the OSNRC. GR is employed by ResMed Ltd., which co-developed the OSNRC and may commercialize the OSNRC in the future.

Author details
1. Infectious Diseases Research Collaboration, Kampala, Uganda. 2. Department of Pediatrics and Child Health, Mulago National Referral Hospital and Makerere University, Kampala, Uganda. 3. Department of Pediatrics, Makerere University College of Health Sciences, Kampala, Uganda. 4. Department of Medicine, Makerere University College of Health Sciences, Kampala, Uganda. 5. Intellectual Ventures, Global Good Fund, Bellevue, WA, USA. 6. Department of Pediatrics, University of Alberta, 3-588D Edmonton Clinic Health Academy, 11405 87 Ave NW, Edmonton, Alberta T6G 1C9, Canada. 7. ResMed Ltd., Bella Vista, Australia. 8. Present address: Issaquah, USA. 9. Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Canada. 10. School of Public Health, University of Alberta, Edmonton, Canada. 11. Stollery Science Lab, Edmonton, Canada. 12. Women and Children’s Health Research Institute, Edmonton, Canada.

Received: 26 March 2020 Accepted: 18 August 2020
Published online: 31 August 2020

References
1. Liu L, Oza S, Hogan D, Perin J, Rudan I, Lawn JE, Cousens S, Mathers C, Black RE. Global, regional, and national causes of child mortality in 2000–13, with projections to inform post-2015 priorities: an updated systematic analysis. Lancet. 2015;385(9966):430–40.
2. Lazzarini M, Sonego M, Pellegrin MC. Hypoxaemia as a mortality risk factor in acute lower respiratory infections in children in low and middle-income countries: systematic review and meta-analysis. PLoS One. 2015;10(9): e0136166.
3. Pneumonia. Fact sheet N°331 [http://www.who.int/mediacentre/factsheets/fs331/en/].
4. Opie and Lokken A, Gano K, Mathew K, Bhatia P, Myles S, et al. Inhaled oxygen for children with severe and moderate respiratory illness: a systematic review and meta-analysis. Respiration. 2017;93(3):253–65.
5. Pneumonia. Fact sheet N°331 [http://www.who.int/mediacentre/factsheets/fs331/en/].
6. Oto J, Chenelle C, Marchese A, Kacmarek R. A comparison of leak at the face mask versus the reservoir cannula in pediatric patients with severe hypoxemia. Arch Pediatr Adolesc Med. 2004;158(6):555–60.
27. Christopher K, Spofford P, Brannin B, Petty T. The safety, efficacy and efficiency of a new transtracheal procedure and catheter. Am Rev Respir Dis. 1986;133:209.
28. Kililloff L, Dauber H, Ferson D, Openbrier D. Nasal cannula and transtracheal delivery of oxygen. Chest. 1984;86:313.
29. Bliss PL, McCoy RW, Adams AB. Characteristics of demand oxygen delivery systems: maximum output and setting recommendations. Respir Care. 2004; 49(2):160–5.
30. Tiep BL, Belman MJ, Mittman C, Phillips R, Otsap B. A new pendant storage oxygen-conserving nasal cannula. Chest. 1985;87(3):381–3.
31. Claiborne RA, Paynter DE, Dutt AK, Rowlands JM. Evaluation of the use of an oxygen conservation device in long-term oxygen therapy. Am Rev Respir Dis. 1987;136(5):1095–8.
32. Wu G, Wollen A, DiBlasi R, Himley S, Saxon E, Austin G, Delarosa J, Izadnegahdar R, Ginsburg A, Zehrung D. Reservoir cannulas for pediatric oxygen therapy: a proof-of-concept study. Int J Pediatr. 2016;2016:9214389.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.